Trajectories of body mass index and waist circumference before the onset of diabetes among people with prediabetes.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
09 2020
Historique:
received: 28 08 2019
revised: 17 11 2019
accepted: 19 12 2019
pubmed: 14 1 2020
medline: 7 8 2021
entrez: 14 1 2020
Statut: ppublish

Résumé

To investigate trajectories of body mass index (BMI) and waist circumference (WC) among prediabetic people who progressed to diabetes, people who remained with prediabetes, and those who returned to normoglycemia. We used data from 22,945 prediabetic people who received an annual health checkup for up to eight years. The development of diabetes was defined using the American Diabetes Association criteria. People who did not progress to diabetes during the observation period were classified as 'remained with prediabetes' or 'returned to normoglycemia', based on their last health checkup data. Trajectories of BMI and WC were evaluated using linear mixed models for repeated measures, with adjustment for a wide range of covariates. During the study period, 2972 people progressed to diabetes, 4706 returned to normoglycemia, and 15,267 remained with prediabetes. People who progressed to diabetes had a larger increase in mean BMI from 7 years to 1 year prior to diagnosis, which was about three times that of people who remained with prediabetes (annual change rate, 0.20 [95% confidence interval; 0.15 to 0.24] vs 0.06 [0.04 to 0.08] kg/m Our study provides strong evidence that avoiding weight gain could help prediabetic people minimize the risk of developing diabetes, regardless of whether they are obese. Losing weight could help obese people restore normoglycemia from a prediabetic state, whereas maintaining current weight may help nonobese people return to normoglycemia.

Sections du résumé

BACKGROUND & AIMS
To investigate trajectories of body mass index (BMI) and waist circumference (WC) among prediabetic people who progressed to diabetes, people who remained with prediabetes, and those who returned to normoglycemia.
METHODS
We used data from 22,945 prediabetic people who received an annual health checkup for up to eight years. The development of diabetes was defined using the American Diabetes Association criteria. People who did not progress to diabetes during the observation period were classified as 'remained with prediabetes' or 'returned to normoglycemia', based on their last health checkup data. Trajectories of BMI and WC were evaluated using linear mixed models for repeated measures, with adjustment for a wide range of covariates.
RESULTS
During the study period, 2972 people progressed to diabetes, 4706 returned to normoglycemia, and 15,267 remained with prediabetes. People who progressed to diabetes had a larger increase in mean BMI from 7 years to 1 year prior to diagnosis, which was about three times that of people who remained with prediabetes (annual change rate, 0.20 [95% confidence interval; 0.15 to 0.24] vs 0.06 [0.04 to 0.08] kg/m
CONCLUSIONS
Our study provides strong evidence that avoiding weight gain could help prediabetic people minimize the risk of developing diabetes, regardless of whether they are obese. Losing weight could help obese people restore normoglycemia from a prediabetic state, whereas maintaining current weight may help nonobese people return to normoglycemia.

Identifiants

pubmed: 31926761
pii: S0261-5614(19)33211-X
doi: 10.1016/j.clnu.2019.12.023
pii:
doi:

Substances chimiques

Blood Glucose 0
Lipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2881-2888

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare there is no conflict of interest.

Auteurs

Huan Hu (H)

Department of Epidemiology and Prevention, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: hu.huanhuan@yahoo.com.

Yohei Kawasaki (Y)

Biostatistics Section, Clinical Research Center, Chiba University Hospital, Chiba, Japan.

Keisuke Kuwahara (K)

Department of Epidemiology and Prevention, National Center for Global Health and Medicine, Tokyo, Japan; Teikyo University Graduate School of Public Health, Tokyo, Japan.

Tohru Nakagawa (T)

Hitachi, Ltd., Ibaraki, Japan.

Toru Honda (T)

Hitachi, Ltd., Ibaraki, Japan.

Shuichiro Yamamoto (S)

Hitachi, Ltd., Ibaraki, Japan.

Masafumi Eguchi (M)

Furukawa Electric Co., Ltd., Tokyo, Japan.

Takeshi Kochi (T)

Furukawa Electric Co., Ltd., Tokyo, Japan.

Akiko Nishihara (A)

Azbil Corporation, Tokyo, Japan.

Teppei Imai (T)

Azbil Corporation, Tokyo, Japan.

Makoto Yamamoto (M)

Yamaha Corporation, Shizuoka, Japan.

Hiroko Okazaki (H)

Mitsui Chemicals, Inc., Tokyo, Japan.

Toshiaki Miyamoto (T)

Nippon Steel Corporation Kimitsu Works, Chiba, Japan.

Kentaro Tomita (K)

Mitsubishi Plastics, Inc., Tokyo, Japan.

Akihiko Uehara (A)

Seijinkai Shizunai Hospital, Hokkaidō, Japan.

Takayuki Ogasawara (T)

Mitsubishi Fuso Truck and Bus Corporation, Kanagawa, Japan.

Naoko Sasaki (N)

Mitsubishi Fuso Truck and Bus Corporation, Kanagawa, Japan.

Ai Hori (A)

Department of Global Public Health, University of Tsukuba, Ibaraki, Japan.

Satsue Nagahama (S)

All Japan Labour Welfare Foundation, Tokyo, Japan.

Makiko Shimizu (M)

Mizue Medical Clinic, Keihin Occupational Health Center, Kanagawa, Japan.

Taizo Murakami (T)

Mizue Medical Clinic, Keihin Occupational Health Center, Kanagawa, Japan.

Sanmei Chen (S)

Department of Epidemiology and Prevention, National Center for Global Health and Medicine, Tokyo, Japan.

Isamu Kabe (I)

Furukawa Electric Co., Ltd., Tokyo, Japan.

Tetsuya Mizoue (T)

Department of Epidemiology and Prevention, National Center for Global Health and Medicine, Tokyo, Japan.

Tomofumi Sone (T)

National Institute of Public Health, Saitama, Japan.

Seitaro Dohi (S)

Mitsui Chemicals, Inc., Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH